Proton Therapy vs IMRT in Prostate Cancer PARTIQoL Trial - Jason Efstathiou
September 27, 2024
Jason Efstathiou about the results of the PARTIQoL Trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou reveals that the study found no significant differences in tumor control or patient-reported quality of life between the two treatment modalities for low and intermediate-risk prostate cancer patients. He emphasizes the importance of this first-of-its-kind trial in evaluating radiation technologies with the same rigor as drug trials, highlighting its patient-centered approach and significance in advancing the field of radiation oncology.
Biographies:
Jason Efstathiou, MD, DPhil, Professor of Radiation Oncology at Harvard Medical School, Vice-Chair of Faculty & Academic Affairs and Director of the Genitourinary (GU) Division in the Department of Radiation Oncology, Clinical Co-Director of The Claire and John Bertucci Center for GU Cancers at Massachusetts General Hospital, Boston, MA
E. David Crawford, MD, Urologist, Professor of Urology, Jack A. Vickers Director of Prostate Cancer Research, University of California San Diego, San Diego Health, San Diego, CA, The University of Colorado Anschutz Medical Campus, Aurora, CO
Biographies:
Jason Efstathiou, MD, DPhil, Professor of Radiation Oncology at Harvard Medical School, Vice-Chair of Faculty & Academic Affairs and Director of the Genitourinary (GU) Division in the Department of Radiation Oncology, Clinical Co-Director of The Claire and John Bertucci Center for GU Cancers at Massachusetts General Hospital, Boston, MA
E. David Crawford, MD, Urologist, Professor of Urology, Jack A. Vickers Director of Prostate Cancer Research, University of California San Diego, San Diego Health, San Diego, CA, The University of Colorado Anschutz Medical Campus, Aurora, CO
Related Content:
ASTRO 2024: Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Localized Prostate Cancer
PARTIQoL Trial: Proton Therapy vs IMRT for Localized Prostate Cancer - Jason Efstathiou
Radiation Therapy Options for Localized Prostate Cancer Compared in Major Trial - Jason Efstathiou
ASTRO 2024: Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Localized Prostate Cancer
PARTIQoL Trial: Proton Therapy vs IMRT for Localized Prostate Cancer - Jason Efstathiou
Radiation Therapy Options for Localized Prostate Cancer Compared in Major Trial - Jason Efstathiou
Read the Full Video Transcript
E. David Crawford: Hi, everyone. My name is E. David Crawford. We had the opportunity to talk with Dr. Jason Efstathiou from Harvard. He's a radiation oncologist, about a trial called the PARTIQoL Trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. He highlighted the potential benefits of proton therapy and the challenges of conducting comparative studies. The trial focuses on patient-reported outcomes, particularly bowel function at 24 months. A lot of innovative strategies, such as electronic questionnaires, patient-centered initiatives, and minority recruitment efforts, were all used to enhance accrual. The trial includes 450 patients from 29 centers. Jason emphasized the need for rigorous data to assess the benefits of proton therapy, which is still limited in availability around the United States. Today, his abstract, which was submitted and accepted for ASTRO, is being released, and Jason is now going to share with us the information which is in the abstract, which gives us some focus on the early results of this study. Jason, thanks for being with us.
Jason Efstathiou: Yeah, Dave. The PARTIQoL Trial showed that patients with low and intermediate-risk prostate cancer who were treated with either proton beam therapy or intensity-modulated radiation therapy achieved equally high rates of tumor control with no differences in patient-reported quality of life. This is a first-of-its-kind Phase III clinical trial that compared those two technologies for one of the most common cancers in the world, and I believe our results represent a win for the field of radiation oncology overall. It was also a trial, very much designed to put patients first, and what I mean by that is, it was a really important undertaking to evaluate technologies we're using to treat patients with the same rigor that clinical trials employ for new drugs and therapies.
E. David Crawford: Absolutely a trailblazing study, and I think this sets a pretty high bar going forward in clinical trials. Thanks very much for your time.
Jason Efstathiou: Thanks so much, Dave.
E. David Crawford: Hi, everyone. My name is E. David Crawford. We had the opportunity to talk with Dr. Jason Efstathiou from Harvard. He's a radiation oncologist, about a trial called the PARTIQoL Trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. He highlighted the potential benefits of proton therapy and the challenges of conducting comparative studies. The trial focuses on patient-reported outcomes, particularly bowel function at 24 months. A lot of innovative strategies, such as electronic questionnaires, patient-centered initiatives, and minority recruitment efforts, were all used to enhance accrual. The trial includes 450 patients from 29 centers. Jason emphasized the need for rigorous data to assess the benefits of proton therapy, which is still limited in availability around the United States. Today, his abstract, which was submitted and accepted for ASTRO, is being released, and Jason is now going to share with us the information which is in the abstract, which gives us some focus on the early results of this study. Jason, thanks for being with us.
Jason Efstathiou: Yeah, Dave. The PARTIQoL Trial showed that patients with low and intermediate-risk prostate cancer who were treated with either proton beam therapy or intensity-modulated radiation therapy achieved equally high rates of tumor control with no differences in patient-reported quality of life. This is a first-of-its-kind Phase III clinical trial that compared those two technologies for one of the most common cancers in the world, and I believe our results represent a win for the field of radiation oncology overall. It was also a trial, very much designed to put patients first, and what I mean by that is, it was a really important undertaking to evaluate technologies we're using to treat patients with the same rigor that clinical trials employ for new drugs and therapies.
E. David Crawford: Absolutely a trailblazing study, and I think this sets a pretty high bar going forward in clinical trials. Thanks very much for your time.
Jason Efstathiou: Thanks so much, Dave.